MSB 2.29% $1.28 mesoblast limited

2023 The Final Countdown, page-1246

  1. 17,167 Posts.
    lightbulb Created with Sketch. 2422
    "Primary gain is ours as a society. Children having the opportunity to survive & thrive. Parents buying their children toys rather than having to choose a coffin for them. Because that’s what in reality it actually comes down to"

    No it isn't, because even with the favourable outcome touted by SI, survival is still only 50% not the 100% you are implying, and even that outcome wasn't supported by the results of the two previous RCTs carried out by Osiris. And the p value of the open label trial depends on the hypothetical control group that is different depending on which study you choose to quote. The Osiris trials had favourable phase 2 trials as well that weren't confirmed in the phase 3 RCTs. That's what concerns SI and its the real reason he doesn't want to take the chance on a proper RCT. Really the aGVHD trial is of a size, design and quality you would expect from a phase 2 trial not a phase 3 pivotal trial for the FDA.

    Just to remind you of the outcomes of the Osiris trials

    https://www.evaluate.com/vantage/articles/news/osiris-left-clinging-niche-after-prochymal-failure
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.28
Change
-0.030(2.29%)
Mkt cap ! $1.461B
Open High Low Value Volume
$1.32 $1.35 $1.28 $1.677M 1.289M

Buyers (Bids)

No. Vol. Price($)
10 44452 $1.28
 

Sellers (Offers)

Price($) Vol. No.
$1.29 23596 1
View Market Depth
Last trade - 16.10pm 04/11/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.